Premium
Resveratrol prevents RV/T changes in a neonatal model of hypoxia induced pulmonary hypertension
Author(s) -
Slutzky Jessica Lauren,
Natale Elizabeth K,
Sprinkle Spencer L,
Chicoine Louis G
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.619.1
Subject(s) - resveratrol , hypoxia (environmental) , pulmonary hypertension , ventricle , medicine , endocrinology , anesthesia , pharmacology , chemistry , oxygen , organic chemistry
Resveratrol (trans‐3,5,4′‐trihydroxystilbene) is a polyphenolic compound found in red wine and possesses anti‐inflammatory, antioxidant, and antifibrotic properties. We tested the hypothesis that daily resveratrol treatment would attenuate the development of hypoxia induced pulmonary hypertension (PHT). Two day old Spague‐Dawley rats were treated with daily SQ injections of resveratrol (100 mg/kg) or vehicle and placed in normoxia or hypobaric hypoxia (435 torr) for 14 days. Measurement of right ventricle wall weight divided by the total heart weight (RV/T) was used as a measure of PHT. RV/T was greatest in vehicle treated neonatal rats exposed to chronic hypoxia (0.46 ± 0.03, P<0.05 compared to the other 3 groups), whereas, normoxic vehicle treated (0.23 ± 0.02), normoxic resveratrol treated (0.24 ± 0.02), and hypoxic resveratrol treated (0.29 ± 0.03) RV/T where not different from each other. Hypoxic exposure resulted in lower (P<0.05) body weights than in normoxic exposure, and resveratrol did not affect body weight in either normoxic or hypoxic pups (weight at harvest was 36.0 ± 0.8 g normoxic vehicle, 39.3 ± 1.3 g normoxic resveratrol, 27.1 ± 1.2 g hypoxic vehicle, and 25.6 ± 1.1 g hypoxic resveratrol). These results suggest that resveratrol prevents chronic hypoxia induced pulmonary hypertension and may be clinically useful in the treatment of pulmonary hypertensive disease.